Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CLGN 
Collplant Biotechnologies Ltd (CLGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: CLGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11.56
1 Year Target Price $11.56
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -49.02% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 28.99M USD | Price to earnings Ratio - | 1Y Target Price 11.56 |
Price to earnings Ratio - | 1Y Target Price 11.56 | ||
Volume (30-day avg) 1 | Beta 0.79 | 52 Weeks Range 1.31 - 4.98 | Updated Date 11/3/2025 |
52 Weeks Range 1.31 - 4.98 | Updated Date 11/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1775.42% |
Management Effectiveness
Return on Assets (TTM) -37.9% | Return on Equity (TTM) -78.25% |
Valuation
Trailing PE - | Forward PE 15.55 | Enterprise Value 22874394 | Price to Sales(TTM) 12.07 |
Enterprise Value 22874394 | Price to Sales(TTM) 12.07 | ||
Enterprise Value to Revenue 9.52 | Enterprise Value to EBITDA -5.97 | Shares Outstanding 12716014 | Shares Floating 8357092 |
Shares Outstanding 12716014 | Shares Floating 8357092 | ||
Percent Insiders 10.16 | Percent Institutions 12.23 |
Upturn AI SWOT
Collplant Biotechnologies Ltd
Company Overview
History and Background
Collplant Biotechnologies Ltd. was founded in 2004 in Israel and focuses on the development and commercialization of recombinant human collagen (rhCollagen) based products. It went public in 2015 on the NASDAQ.
Core Business Areas
- Regenerative Medicine: Developing and manufacturing rhCollagen-based products for tissue repair and regeneration.
- Aesthetics: Developing rhCollagen-based dermal fillers and aesthetic treatments.
- Bioprinting: Exploring the use of rhCollagen in bioprinting applications for creating functional tissues and organs.
Leadership and Structure
Yehiel Tal serves as the Chief Executive Officer. The company has a board of directors and operates with functional departments overseeing R&D, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Vertebral Body: rhCollagen based product used for spinal fusions. It's a substitute for autograft bone. Limited market share data available, competition includes Medtronic (MDT), Stryker (SYK).
- Dermal Fillers: rhCollagen-based dermal fillers are in development. Competition includes Allergan (ABBV), Galderma.
- Bioprinted Lungs: CollPlant is working towards 3D bioprinted lungs using their rhCollagen. Competing with larger research entities and bioprinting companies.
Market Dynamics
Industry Overview
The regenerative medicine and aesthetics markets are growing, driven by aging populations and demand for advanced therapies.
Positioning
Collplant is positioned as an innovator in rhCollagen-based products, aiming to capture market share in regenerative medicine and aesthetics.
Total Addressable Market (TAM)
The total addressable market for regenerative medicine and aesthetics is multi-billion dollar. Collplant is positioned to gain share through unique rhCollagen technology.
Upturn SWOT Analysis
Strengths
- Proprietary rhCollagen technology
- Strong IP portfolio
- Strategic partnerships
Weaknesses
- Limited commercialized products
- Reliance on partnerships
- Significant R&D expenses
Opportunities
- Expanding into new therapeutic areas
- Gaining regulatory approvals
- Strategic acquisitions
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- MDT
- ABBV
- SYK
Competitive Landscape
Collplant faces competition from established medical device and pharmaceutical companies with greater resources. Its competitive advantage lies in its unique rhCollagen technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by pre-clinical trial results and partnership agreements.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercialization efforts.
Recent Initiatives: Focus on the development of rhCollagen-based products, specifically bioprinted lungs, and dermal fillers.
Summary
Collplant Biotechnologies is a biotech company focusing on regenerative medicine using recombinant human collagen. The company has some strengths in IP and strategic partnerships, but has weaknesses such as limited commercialized products. The company is dependent on clinical trials and regulatory approvals. Investors should watch for clinical results and partnership announcements to determine how well it is doing.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investing in biotech companies involves significant risks. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Collplant Biotechnologies Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-01-30 | CEO & Director Mr. Yehiel Tal | ||
Sector Healthcare | Industry Biotechnology | Full time employees 57 | Website https://collplant.com |
Full time employees 57 | Website https://collplant.com | ||
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel for the treatment of chronic and acute wounds. The company also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. It has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.